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Rationale: Volatile organic compounds (VOCs) in breath provide biomarkers of tuberculosis (TB) because
Mycobacterium tuberculosis manufactures VOC metabolites that are detectable in the breath of infected
patients.
Objectives: We evaluated breath VOC biomarkers in subjects with active pulmonary TB, using an internetlinked rapid point-of-care breath test.
Methods: 279 subjects were studied at four centers in three countries, Philippines, UK, and India, and data
was analyzed from 251 (130 active pulmonary TB, 121 controls). A point-of-care system collected and
concentrated breath and air VOCs, and analyzed them with automated thermal desorption, gas chromatography, and surface acoustic wave detection. A breath test was completed in 6 min. Chromatograms
were converted to a series of Kovats Index (KI) windows, and biomarkers of active pulmonary TB were
identiﬁed by Monte Carlo analysis of KI window alveolar gradients (abundance in breath minus abundance in room air).
Measurements and main results: Multiple Monte Carlo simulations identiﬁed eight KI windows as
biomarkers with better than random performance. Four KI windows corresponded with KI values of
VOCs previously identiﬁed as biomarkers of pulmonary TB and metabolic products of M. tuberculosis,
principally derivatives of naphthalene, benzene and alkanes. A multivariate predictive algorithm identiﬁed active pulmonary TB with 80% accuracy (area under curve of receiver operating characteristic
curve), sensitivity ¼ 71.2%, and speciﬁcity ¼ 72%. Accuracy increased to 84% in age-matched subgroups.
In a population with 5% prevalence, the breath test would identify active pulmonary TB with 98%
negative predictive value and 13% positive predictive value.
Conclusions: A six-minute point-of-care breath test for volatile biomarkers accurately identiﬁed subjects
with active pulmonary TB.
Ó 2012 Elsevier Ltd. All rights reserved.
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An estimated 2 billion people, one third of the world’s population, are infected with Mycobacterium tuberculosis.1 Tuberculosis
(TB) remains a leading cause of death from infectious disease, with
an estimated 9.4 million new cases throughout the world every
year.2 Sputum smear microscopy remains the mainstay of diagnosis
in resource-poor countries with a high TB burden, but the low
sensitivity of this test results in patients with smear-negative but
culture-positive pulmonary TB passing undetected through the
health care system.3 The high incidence of smear-negative TB in
patients infected with HIV has further highlighted the clinical need
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for tests for TB that are not only sensitive and speciﬁc, but also
rapid, non-invasive, and cost-effective.4
A breath test for volatile organic compounds (VOCs) could
provide a rational test for active pulmonary TB because the causative organism, M. tuberculosis, manufactures VOC metabolites
in vitro, and a number of these VOCs have been detected in the
breath as apparent biomarkers of infection.5,6 Breath biomarkers
identiﬁed active pulmonary tuberculosis (TB) with 85% accuracy in
a multicenter international study employing a breath collection
apparatus (BCA) and VOC analysis with automated thermal
desorption, gas chromatography and mass spectrometry (ATD-GCMS).7 Breath testing for active pulmonary TB appears rational and
feasible, but clinical application has been limited by the cost of
ATD-GC-MS and the requirement for highly trained technical staff.
However, recent advances in sensitive and cost-effective analytical
instruments have enabled breath VOC microanalysis at a clinical
point-of-care without the requirement for specialized laboratory
resources. We report here an analytical system that was developed for
rapid point-of-care collection and analysis of breath VOCs, and the
evaluation of this system in a multicenter international study of breath
VOC biomarkers in patients with active pulmonary TB.
1. Materials and methods
1.1. Clinical sites
Four tuberculosis treatment centers participated in the study, in
the Philippines (University of Santo-Tomas, Manila, and De La Salle
Health Sciences Institute, Cavite), UK (Homerton University
Hospital, London) and India (Hinduja Hospital, Mumbai & Sir JJ
Group of Hospitals, Mumbai).
1.2. IRB approval and informed consent
An Institutional Review Board (IRB) at each collaborating site
approved the research. All subjects gave their signed informed
consent to participate. Assent from adolescent subjects and consent
from a parent or legal guardian was obtained for subjects 13e16 yr
in England or younger than 18 yr at sites in other countries.
1.3. Human subjects
279 subjects were recruited according to the following criteria:
1.3.1. Control group e inclusion criteria
1. Subject is older than 13 years of age
2. Subject is undergoing screening for pulmonary TB without
clinical evidence of active TB
1.3.2. Exclusion criteria
1. Clinical suspicion of pulmonary TB based on: symptoms and
signs e.g. cough, sputum production, night sweats, weight loss
or hemoptysis
OR: history of known recent exposure to infection
OR: chest X-ray abnormalities consistent with active
pulmonary TB
2. Positive sputum smear test or positive sputum culture.
1.3.3. Disease group e inclusion criteria
1. Subject is older than 13 years of age
2. Clinical suspicion of pulmonary TB based on: symptoms and
signs e.g. cough, sputum production, night sweats, weight loss
or hemoptysis
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OR: history of known recent exposure to infection
OR: chest X-ray abnormalities
OR: positive sputum smear consistent with active pulmonary
TB
OR: sputum culture results positive or pending
1.3.4. Exclusion criteria
1. Subject is currently taking anti-TB therapy or has received more
than 7 days of anti-TB therapy in the past six months
1.4. Point-of-care breath test
The BreathLink system developed for this study comprised three
main components:
1. Breath VOC sample collector and concentrator (BCA): The front
end of the system, the BCA method for collection and
concentration of alveolar breath VOC samples has been
described.7 In summary, a subject wore a nose-clip and
respired normally for 2.0 min, inspiring room air from a valved
mouthpiece, and expiring into a breath reservoir through with
a bacterial ﬁlter. The valved mouthpiece and the bacterial ﬁlter
were disposed after use. A one-way outlet valve in the
mouthpiece prevented backﬂow of breath into the mouth, and
the 6-micron bacterial ﬁlter blocked transmission of Mycobacteria or other microorganisms. The mouthpiece and ﬁlter
presented low resistance to expiration, so that subjects could
donate breath samples without effort or discomfort. Alveolar
breath VOCs were pumped from the breath reservoir through
a sorbent trap where they were captured and concentrated.
VOCs in a similar volume of room air were separately collected
and concentrated in the same fashion.
2. Breath VOC analyzer: An analyzer was developed for the
BreathLink system, employing a portable gas chromatograph
coupled to a surface acoustic wave (SAW) detector. The VOC
sample was thermally desorbed from the sorbent trap in
a stream of helium carrier gas and separated on a GC column
with thermal ramping. VOCs were detected with a single nonfunctionalized SAW solid-state mass-sensitive detector with
picomolar sensitivity and universal selectivity; the principles
have been reported.8 The analyzer was calibrated daily with an
external standard, a mixture of C6 to C22 n-alkanes (Restek
Corporation, Bellefonte, PA 16823, USA). Each breath test
comprising collection and analysis of separate samples of
breath and room air was completed within 6 min.
3. Control software: Custom software was developed for the
BreathLink system and installed on a secure computer at the
point-of-care where it performed the following functions:
a Control of instrument functions. The software automatically
controlled breath and air sample collections with the BCA,
and analysis with the breath VOC analyzer.
b Electronic Case Report Form (eCRF): Collaborators at clinical
sites entered subject data into an electronic case report form
(eCRF) with a unique identiﬁcation number. Subject names
were not recorded, except in a separate conﬁdential log
maintained at the clinical site. A menu-driven program prevented collection of a breath sample unless all inclusion and
exclusion criteria were fulﬁlled. The eCRF comprised demographic data and clinical information including chest X-ray
reports and results of sputum smear microscopy and culture.
c File storage, encryption, and transmission: Files containing
de-identiﬁed chromatographic raw data and eCRFs were
stored locally on the computer, then encrypted and transmitted via the internet to a server at the Menssana Research
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Breath Research laboratory in Newark, NJ, USA, where they
were decrypted and stored for analysis. An industry standard hypertext transfer protocol secure (https) connection
ensured data security.
Instrument detection limit is deﬁned as the analyte concentration
that is required to produce a signal greater than three times the
standard deviation of the noise level9 and was determined for tridecane (Sigma Aldrich, St. Louis, MO 63103) serially diluted in
methanol.
1.5. Analysis of data
In summary, the retention time of each chromatographic peak
was normalized according to its Kovats Index (KI) (retention time
relative to known n-alkane standards)10,11 and the chromatogram
was converted into a series of data points by segmenting it into
a series of 100 KI windows. The alveolar gradient of each KI
window (i.e. abundance in alveolar breath minus abundance in
ambient room air) was determined as: alveolar gradient ¼ Vb/
IbVa/Ia where Vb ¼ integrated abundance of VOCs in breath
observed with SAW detector, and Ib ¼ area under the curve (AUC)
of the chromatographic peak associated with the external control
standard. Va and Ia were corresponding values observed in the
associated sample of ambient room air. The alveolar gradient
varies with rate of synthesis of a VOC minus its rate of clearance,
so that a positive value indicates that a VOC was synthesized at
a greater rate than it was cleared from the body, and vice versa for
a negative value.12,13
1.6. Identiﬁcation of biomarkers and construction of predictive
algorithm
Multiple Monte Carlo simulations were employed to identify the
KI windows that identiﬁed disease with greater than random

accuracy. The method has been described.7 In summary, the alveolar gradients of all KI windows were compared in the disease and
control groups and ranked as candidate biomarkers according to
their C-statistic values i.e. the AUC of the receiver operating characteristic (ROC) curve.14 The average random behavior of each
chromatographic KI window was determined with multiple Monte
Carlo simulations by randomly assigning subjects to the disease or
control group, and performing 40 estimates of the C-statistic value.
Differences between the C-statistic values obtained with correct
diagnosis and random diagnosis identiﬁed the KI windows that
were true biomarkers, because they identiﬁed the disease group
with better than random accuracy.15,16 The KI windows identiﬁed as
biomarkers of disease were employed to construct a multivariate
predictive algorithm with weighted digital analysis (WDA).17
1.7. Comparison of KI windows to previously reported biomarkers
KI window values were compared to KI values of previously
reported VOC biomarkers of active pulmonary TB5,7 employing
a database maintained by the National Institute of Standards and
Technology (NIST Standard Reference Database Number 69).18 Also,
pure samples of benzene, 1,3,5-trimethyl- and toluene were
analyzed with the BreathScanner GC-SAW.
2. Results
2.1. Human subjects
279 subjects fulﬁlled recruitment criteria and 251 were entered
into data analysis. Characteristics and exclusions are shown in
Table 1. No adverse effects of the breath test were reported.
Instrument detection limit requirements were fulﬁlled by 0.1 mL
of 0.1 ppt tridecane solution, which was equivalent to less than
1012 mol tridecane in a breath sample.

Table 1
Characteristics of human subjects.
Control group

Technical quality of breath test

Site

No. recruited

Unsatisfactory

Satisfactory

Cavite
London
Manila
Mumbai
Total
Male
Female
Total

47
17
52
22
138

5
4
6
2
17

42
13
46
20
121
53
68
121

Disease group

Technical quality of breath test

Site

No. recruited

Unsatisfactory

Satisfactory

Cavite
London
Manila
Mumbai
Total
Male
Female
Total

30
3
60
48
141

0
0
4
7
11

30
3
56
41
130
86
44
130

Smear positive

Culture-positive

Chest X-ray positive

Total positive**

30
1
56
38
126

30
3
55
7
96

30
3
56
41
130

30
3
56
41
130

Age (yr)

Controls

Disease group

Mean
SD

33.31
13.46

40.86
16.57

p < 0.0001.
2-tailed t-test.
All subjects with technically unsatisfactory breath test samples were excluded from analysis. Subjects who were initially recruited to the control group but were found to have
a positive sputum culture or a positive sputum smear, or a chest X-ray consistent with active pulmonary TB were transferred to the disease group. Inclusions in the disease
group. **Subjects were included as positive for active pulmonary TB and entered into the analysis of data if they had a positive sputum culture and/or positive sputum smear
microscopy and/or chest X-ray consistent with active pulmonary TB.
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2.2. Identiﬁcation of KI window biomarkers
Multiple Monte Carlo simulations identiﬁed eight chromatographic KI windows as biomarkers with better than random performance (Figure 1a). Figure 2 displays KI values of these biomarkers in
controls and in subjects with pulmonary TB in a heatmap of chromatographic alveolar gradients. Four KI window biomarkers corresponded with KI values of VOCs previously reported as biomarkers of
pulmonary TB and in vitro metabolites of M. tuberculosis5e7 (Table 2).
2.2.1. Predictive algorithm and ROC curve
The WDA multivariate predictive algorithm identiﬁed active
pulmonary TB with 80% accuracy. Cumulative accuracy of the
algorithm and ROC curve are shown in Figure 1b and c.
2.2.2. Positive and negative predictive values (PPV and NPV)
Figure 1d displays the expected variation of PPV with NPV of the
test in a high-burden setting with 5% prevalence of active

pulmonary TB, and Figure 3 displays the expected outcome when
a combination of sensitivity and speciﬁcity values was selected to
result in NPV ¼ 98%.
2.3. Effect of age on accuracy of predictive algorithm
Patient subsets were selected in the age range 30e65 yr
(controls n ¼ 45, mean ¼ 43.89 yr, SD ¼ 10.9, disease group
n ¼ 72, mean ¼ 46.1 yr, SD ¼ 10.14, 2-tailed t-test p ¼ 0.26, NS).
When the same predictive algorithm was applied to these subsets,
AUC of ROC curve ¼ 0.84.
3. Discussion
The main ﬁnding of this study was that a model based on
a point-of-care breath test for volatile biomarkers identiﬁed active
pulmonary TB with 80% accuracy overall, increasing to 84% accuracy in age-matched subsets. This was consistent with our previous

b

No. KI windows

Mean of
multiple
Monte Carlo
simulations

Correct
Random
Random + 1 SD

Cumulative C-statistic of algorithm

a
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Accuracy of
predictive
algorithm

No. KI windows in algorithm

Sensitivity (TPR)

c

sensitivity = 71.2%
specificity = 72%
AUC = 0.80

d

40

Positive predictive value (PPV) %

C-statistic cutoff value

35

30

25

20

15

10

5

0
95

1-specificity (FPR)

96

97

98

99

100

Negative predictive value (NPV) %

Figure 1. Analysis of breath VOC data. Top left panel 1a: Monte Carlo identiﬁcation of signiﬁcant biomarkers. The “correct” curve shows the number of KI windows with the highest
C-statistic values that correctly identiﬁed pulmonary TB. The C-statistic is the AUC of the ROC curve of a KI window when it was employed alone as a biomarker of disease. The
“random” curve shows the number of KI windows with the highest C-statistic values that identiﬁed pulmonary TB by chance alone. The random C-statistic values of all KI windows
were determined in 40 Monte Carlo simulations in which subjects were randomly assigned to the disease group or the control group. Where C-statistic ¼ 0.64, the “random” curve
fell to <1, but eight KI windows in the “correct” curve identiﬁed the disease group with better than random accuracy. SD ¼ standard deviation. Top right panel 1b: Accuracy of
predictive algorithm. The signiﬁcant biomarker KI windows identiﬁed with Monte Carlo simulations were entered into a multivariate predictive algorithm. The algorithm achieved
80% accuracy with eight biomarkers, and achieved near-maximal accuracy with only three biomarkers. Bottom left panel 1c: Receiver operating characteristic (ROC) curve of
predictive algorithm. The ﬁgure displays true-positive rate (TPR) (sensitivity) versus false-positive rate (FPR) (1-speciﬁcity), and the point on the curve where the sum of sensitivity
plus speciﬁcity was maximal. Bottom right panel 1d: Variation in PPV with NPV. This ﬁgure displays the expected outcome PPV and NPV of the breath test in a high-burden setting
with 5% prevalence of active pulmonary TB, based on the sensitivity and speciﬁcity values shown in the ROC curve.
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Figure 2. Heatmap of chromatographic KI windows. The heatmap displays KI windows in controls (upper panel) and in subjects with active pulmonary TB (lower panel). The
horizontal axis indicates the value of each KI window. The color of each KI window varied on a scale from one to ten (scale shown at right). The scale was calculated for each KI
window by dividing the range between the highest and lowest observed value of the alveolar gradient into ten equal parts. Vertical black lines with adjacent numbered arrows
indicate eight KI windows that were identiﬁed as biomarkers of active pulmonary TB because they were predominantly darker in the controls than in active pulmonary TB, or vice
versa, and multiple Monte Carlo simulations identiﬁed these differences in alveolar gradient as greater than predicted by chance alone. The KI windows indicated with green arrows
corresponded with the KI values of VOCs previously reported as biomarkers of active pulmonary TB and metabolic products of Mycobacterium tuberculosis (see Table 2).

report of a laboratory-based assay for breath biomarkers that
identiﬁed active pulmonary TB with 85% accuracy.7 Four KI
windows corresponded with KI values of VOCs previously identiﬁed as breath biomarkers of pulmonary TB and metabolic products
of M. tuberculosis, principally derivatives of naphthalene, benzene
and alkanes.5e7 This correspondence provides presumptive
evidence from two independent clinical studies that these breath
VOCs are biomarkers of active pulmonary TB.
This study also provided proof of concept that breath
biomarkers identiﬁed in the laboratory with advanced analytical
instruments may be successfully identiﬁed with a point-of-care
system employing a faster and less expensive instrument platform. In practice, the rapid point-of-care breath test combined with
internet transmission of clinical and chromatographic data was
convenient and effective. Clinical sites in countries widely

separated by geography were able to complete a subject’s breath
test in a standardized fashion in 6 min, and pool their data
promptly.
The biological origins of breath VOC biomarkers of active
pulmonary TB were consistent with metabolic products derived
from the infective organism, the host, or both. M. tuberculosis
manufactures a spectrum of VOCs in vitro, including methylated
derivatives of n-alkanes, naphthalene and benzene.5,6 The metabolic source of these products and their biological signiﬁcance are
unknown.
Infection of the host with TB causes increased oxidative stress,
which can result in increased excretion of n-alkanes and their
derivatives in the breath.19e21 The heatmap (Figure 2) demonstrates that different VOCs in the biomarker KI windows were
either increased or decreased in abundance in active pulmonary TB.

Table 2
Correspondence between biomarkers of active pulmonary TB.
Biomarker
number

KI window

Breath biomarker VOCs

Mycobacterium tuberculosis
in vitro VOCs

1&2
3&4

965e1030
1243e1313

camphene; l-beta-pinene; benzene, 1,3,5-trimethylnaphthalene,1-methyl-; tridecane; 1-octanol, 2-butyl; dodecane, 4-methyl

heptane,2,2,4,6,6-pentamethylnaphthalene, 1-methyl-

The point-of-care breath test identiﬁed a group of KI windows as biomarkers of active pulmonary TB (Figure 2). Four of these KI windows corresponded with the KI values of
VOCs previously identiﬁed as breath biomarkers of active pulmonary TB, or VOC products of M. tuberculosis in vitro.5e7 Biomarkers 1, 2, 3 and 4 in this table correspond with
the KI windows indicated by green arrows 1, 2, 3 and 4 in the heatmap (Figure 2). Based on their chromatographic retention times, this correspondence provides presumptive
evidence, though not deﬁnitive proof, that the listed VOCs are similar to those identiﬁed in the heatmap. KI values were obtained from the NIST Standard Reference Database
Number 69.18 GC-SAW analysis of pure samples of benzene, 1,3,5-trimethyl- and toluene yielded similar KI values. The presence of more than one candidate VOC in a single KI
window may have arisen from their coelution in a single peak in the gas chromatogram. The VOC biomarkers listed above are similar, but not identical to those identiﬁed in
previous reports.5e7 These differences may have arisen in part from differences in experimental design, diagnostic criteria and assay methodology. In particular, the assay
parameters and instrumentation employed with the rapid point-of-care ATD-GC-SAW using a short 1 M column would be expected to yield different selectivity and sensitivity
values for breath VOCs compared to the much slower assays with laboratory-based ATD-GC-MS using a 30 M column.
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Figure 3. Predicted outcome of breath test for active pulmonary TB: A speciﬁed target value of NPV or PPV may be achieved by selecting a cutoff point on the ROC curve (Figure 1)
with an appropriate combination of sensitivity and speciﬁcity. In this example, breath testing could achieve a desired target value of NPV ¼ 98% in a population of 10,000 people
with a high (5%) prevalence of active pulmonary TB by selecting a cutoff point on the ROC curve where sensitivity ¼ 71% and speciﬁcity ¼ 75%.

Decreased abundance of breath VOCs may have resulted from
M. tuberculosis catabolizing human metabolic products as nutrients. This hypothesis is consistent with mycobacterial catabolism of
other host-derived nutrients including carbohydrates, amino acids,
phosphate, and cholesterol,22,23 as well as with reports that
alkanes, alkane derivatives or benzene derivatives can all sustain
mycobacterial growth as nutritional substrates.24e26The potential
clinical utility of the point-of-care breath test for active pulmonary
TB may be estimated from its positive and negative predictive
values, which will vary with the prevalence of disease in the study
population. Figure 1 displays the expected values of PPV and NPV in
a population with a high prevalence of active pulmonary TB. In the
example shown in Figure 3, an NPV of 98% was associated with
a PPV of 13%. When the NPV was increased to 99%, the PPV declined
to 10.1%. These ﬁndings illustrate a conundrum that public health
physicians frequently encounter when planning to screen a large
population for a disease: PPV increases as NPV decreases, and vice
versa. The choice of a test cutoff point affects costs as well as patient
beneﬁts. Ideally the NPV should be set as high as possible in order
to minimize the number of infected persons who test as falsenegatives and whose disease goes undetected. However, the PPV
should also be set as high as possible in order to minimize the much
larger number of non-infected persons who test as false-positives,
and who might potentially overwhelm the health care system. In
practice, breath testing might be employed in resource-poor environments as a cost-effective ﬁrst step in a two-stage evaluation
process: Subjects with a negative test result could be reassured that
they not have active pulmonary TB with 98% certainty, so that no
further testing is necessary, while those with a positive test result
could be referred for more costly evaluation with sputum culture
and nucleic acid ampliﬁcation testing (NAAT). Although costs have
not yet been determined, a rapid point-of-care breath test would
probably cost signiﬁcantly less than sputum culture or NAAT
because neither sputum collection nor expensive reagents are
required.
Historically, most advances in breath testing resulted from
innovation in analytical technology. The invention of chemical
colorimetry in the 19th century enabled Anstie to develop the ﬁrst
breath test for alcohol in 1874.27 Nearly 100 years later, advances in
gas chromatography enabled Linus Pauling to discover large
numbers of low-molecular weight VOCs in concentrated human

breath28 Subsequent research has identiﬁed more than 3000
different VOCs in human breath,29 and demonstrated breath VOC
biomarkers in diseases including lung cancer17 and breast cancer.30
Tests employing array technologies have also been proposed to
identify lung cancer and other diseases based on their response to
a unique pattern of breath VOCs31,32; their advantage is simplicity
because they do not employ GC separation of VOCs, however their
disadvantage is that they do not identify or quantify speciﬁc VOCs
in a breath sample. Recent advances in ATD-GC-SAW now enable
breath testing at the clinical point-of-care with sensitivity comparable to laboratory-based ATD-GC-MS, but with instruments that
are smaller, faster, less expensive, and simpler to operate. A
laboratory-based ATD-GC-MS fully equipped for breath VOC analysis currently costs nearly $200,000, while a point-of-care ATD-GCSAW costs only one-tenth as much. Analysis of a breath VOC sample
with laboratory-based ATD-GC-MS employing a 30 M column may
require 60 min of instrument time, while the point-of-care ATDGC-SAW employed in this study analyzed breath VOC samples in
less than one-tenth the time. Despite the disadvantages of lower
selectivity and the lack of MS identiﬁcation of breath VOCs, the
point-of-care ATD-GC-SAW instrument delivered diagnostic
sensitivity and speciﬁcity for active pulmonary TB that was
comparable to laboratory-based ATD-GC-MS. This ﬁnding illustrates that laboratory-based and point-of-care analytical technologies may be complementary rather than competitive.
Although sputum culture is commonly employed as the gold
standard of diagnosis of active pulmonary TB, the test is frequently
inaccurate. Published reports of its accuracy vary widely, with
sensitivity ranging between 40 and 81.5% and speciﬁcity between
85 and 98.4%.33e35 In resource-limited settings, TB is often diagnosed with high accuracy by non-physicians based on acid-fast
bacilli smear, chest X-ray, and clinical history. TB frequently presents a complex diagnostic problem in which different tests
contribute important information to clinical risk assessment.36,37
For this reason, we ranked subjects as positive for active pulmonary TB if they had positive sputum culture and/or positive sputum
smear microscopy and/or chest X-ray consistent with active
pulmonary TB. The diagnostic criteria employed in this study may
have introduced a potential source of error, because the observed
accuracy of a biomarker cannot exceed the accuracy of the diagnostic gold standard to which it is compared. This may be
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illustrated by considering a hypothetical Biomarker X that is 100%
accurate. In a clinical study, all subjects with disease will test
positive for Biomarker X. However, an imperfect gold standard will
generate some false-negatives, so the positive test results from
Biomarker X in these subjects will be scored as false-positives, even
though they were correct in reality. Similarly, false-positive results
with the imperfect gold standard will be scored as false-negatives
for Biomarker X. Consequently, the observed total number of
false-positives and false-negatives will be the same for both the
imperfect gold standard and for Biomarker X, so that the observed
accuracy of Biomarker X will underestimate its true value. Consequently, the 80% accuracy of the breath test for active pulmonary TB
observed in this study may have been an underestimate of its true
value.
We conclude that this is the ﬁrst report of a rapid point-of-care
breath test for VOCs exhaled in picomolar concentrations, and that
this test detected volatile biomarkers of active pulmonary TB
consistent with biomarkers previously reported using laboratorybased instrumentation. The point-of-care breath test was rapid,
accurate, and cost-effective, and could potentially provide a clinically valuable new tool for detection of active pulmonary TB.
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